CT9 Stock Overview
A clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Cardiol Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$1.54 |
| 52 Week High | CA$2.80 |
| 52 Week Low | CA$0.73 |
| Beta | 0.70 |
| 11 Month Change | -11.10% |
| 3 Month Change | -15.12% |
| 1 Year Change | 97.18% |
| 33 Year Change | -20.31% |
| 5 Year Change | n/a |
| Change since IPO | -25.07% |
Recent News & Updates
Recent updates
Shareholder Returns
| CT9 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -13.3% | -7.0% | -0.4% |
| 1Y | 97.2% | -21.6% | 7.1% |
Return vs Industry: CT9 exceeded the German Pharmaceuticals industry which returned -22.4% over the past year.
Return vs Market: CT9 exceeded the German Market which returned 7.8% over the past year.
Price Volatility
| CT9 volatility | |
|---|---|
| CT9 Average Weekly Movement | 12.5% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: CT9's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: CT9's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | n/a | David Elsley | www.cardiolrx.com |
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure.
Cardiol Therapeutics Inc. Fundamentals Summary
| CT9 fundamental statistics | |
|---|---|
| Market cap | €124.17m |
| Earnings (TTM) | -€24.52m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.8x
P/E RatioIs CT9 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CT9 income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$36.14m |
| Earnings | -CA$36.14m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.45 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did CT9 perform over the long term?
See historical performance and comparison